#USA #New York #Class Action #Pomerantz LLP #ARS Pharmaceuticals

Class Action Alert for Investors in ARS Pharmaceuticals

In a significant development for investors in ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), Pomerantz LLP has initiated a class action lawsuit against the company. This alert serves to inform individuals who have suffered financial losses due to their investment in ARS Pharmaceuticals about the ongoing legal proceedings and the urgent need to take action before approaching deadlines.

Legal Grounds of the Class Action

The class action lawsuit centers around allegations of securities fraud perpetrated by ARS and certain executives of the company. Investors are being encouraged to reach out to Pomerantz LLP for more information and to discuss their rights in light of these allegations. The lawsuit's implications could impact the stock price and overall investor perception of ARS Pharmaceuticals.

Contact Information for Affected Investors

Danielle Peyton from Pomerantz is the primary point of contact for investors wishing to learn more about this class action case. Interested parties can contact her via email at [email protected] or by phone at 646-581-9980. It is advisable for investors to include their mailing address and the number of shares they purchased when inquiring.

Deadline for Participation

Investors have until October 5, 2026, to apply for the Lead Plaintiff position in this class action. This deadline is critical for those who acquired ARS securities during the Class Period. To view the full complaint or for guidance on how to join the class action, investors can visit Pomerantz Law's website.

Recent Developments Affecting ARS Pharmaceuticals

The lawsuit follows alarming news released by ARS Pharmaceutical on June 24, 2026. The company announced that it did not secure expanded insurance coverage for its epinephrine nasal spray, known as Neffy, through CVS Caremark by the July 1, 2026 deadline. This lack of insurance coverage is particularly concerning as it affects not only the summer season but also the upcoming back-to-school allergy season. As a result, ARS's stock plummeted by $2.52 per share, marking a significant decline of 23.91% to end at $8.02 per share on June 25, 2026.

This event underscores the potential risks associated with investments in ARS Pharmaceuticals and raises questions about the company’s management and its decision-making processes in regard to product coverage.

About Pomerantz LLP

Pomerantz LLP is renowned for its expertise in corporate, securities, and antitrust class litigation. Established by the pioneer Abraham L. Pomerantz, the firm has a long-standing history of advocating for investors and recovering significant damages on behalf of class members. With offices spanning major cities worldwide, Pomerantz continues to uphold its mission in the legal arena, emphasizing its commitment to fighting for the rights of those affected by securities fraud and corporate misconduct.

For More Information

For further inquiries or legal assistance, affected parties are urged to reach Pomerantz LLP’s dedicated team before the approaching deadline. Ensure your voice is heard in this critical matter.

In conclusion, the situation unfolding alongside ARS Pharmaceuticals highlights the importance of staying informed as an investor and the potential need for legal action when faced with corporate misconduct. It is essential to promptly assess your options and rights in relation to this class action lawsuit, especially before the October deadline approaches.